If you have tried multiple antidepressants without adequate relief, you have likely started researching other options. Two of the most effective advanced treatments for treatment-resistant depression are TMS therapy and SPRAVATO (esketamine). Both are available at Georgia Behavioral Health, and both have strong evidence behind them.
But they work differently, feel different, and are right for different patients.
This guide breaks down exactly what each treatment involves, how they compare, and what factors help determine which one is the better fit.
What Is TMS Therapy?
TMS stands for transcranial magnetic stimulation. It is a non-invasive, outpatient procedure that uses magnetic pulses to stimulate specific regions of the brain involved in mood regulation.
During a TMS session, a device is placed against the scalp and delivers targeted magnetic pulses to the prefrontal cortex, the area of the brain most associated with depression. The pulses are designed to reset the activity of neural circuits that have become dysregulated in patients with depression.
TMS therapy is FDA-cleared for the treatment of major depressive disorder in patients who have not responded adequately to antidepressant medication. It is non-invasive, requires no sedation, and patients can drive themselves to and from appointments.
A standard TMS course involves daily sessions five days a week over approximately six weeks, with each session lasting around 20 to 40 minutes.
What Is SPRAVATO?
SPRAVATO is the brand name for esketamine, a nasal spray derived from ketamine that works on the glutamate system in the brain. Unlike traditional antidepressants, which primarily target serotonin, SPRAVATO targets a completely different neurotransmitter pathway, which is why it can be effective for patients who have not responded to SSRIs or SNRIs.
SPRAVATO is FDA-approved specifically for treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior. It is the only FDA-approved nasal spray for treatment-resistant depression.
Because of the nature of the medication, SPRAVATO is administered in a certified healthcare setting. Patients self-administer the nasal spray under supervision and remain in the clinic for two hours after each session for monitoring. Sessions are typically twice weekly for the first month, then once weekly, then once every one to two weeks for maintenance.
One of SPRAVATO's most notable qualities is the speed of its effect. Many patients experience relief within hours of the first treatment session, making it particularly valuable for patients with more severe or urgent presentations.
TMS vs SPRAVATO: How They Compare
How They Work
TMS works by stimulating brain circuits from the outside using magnetic energy. It does not involve any medication and nothing enters the body. SPRAVATO works pharmacologically, targeting the glutamate system through a nasal spray. Both approaches reach the brain through entirely different mechanisms than traditional antidepressants.
Speed of Results
SPRAVATO tends to produce faster results. Some patients notice improvement within hours of the first session. TMS typically requires several weeks of consistent treatment before significant improvement is felt, though some patients notice changes within the first two weeks.
For patients in acute distress or with more urgent clinical needs, the speed of SPRAVATO can be a significant advantage.
Treatment Schedule
TMS requires a higher time commitment upfront. Daily sessions five days a week for approximately six weeks means roughly 30 in-person visits during the induction phase.
SPRAVATO involves fewer visits, particularly after the initial month. The monitoring requirement means each visit takes two to three hours, but the frequency decreases over time as the patient stabilizes.
Side Effects
TMS side effects are generally mild and localized. The most common are scalp discomfort or headache during or after sessions, which typically diminish after the first few treatments. There is no sedation, no cognitive impairment, and patients can resume normal activities immediately after each session.
SPRAVATO can cause dissociation, dizziness, nausea, and sedation during the monitoring period. These effects are temporary and resolve before the patient leaves the clinic, which is why the two-hour monitoring window is required. Most patients tolerate SPRAVATO well, and the transient side effects often decrease with subsequent sessions.
Insurance Coverage
Both TMS and SPRAVATO are covered by many major insurance plans for patients who meet clinical criteria, typically defined as having failed two or more adequate antidepressant trials. Coverage varies significantly by plan, and prior authorization is usually required for both.
Georgia Behavioral Health works with patients on insurance verification and prior authorization for both treatments. A thorough evaluation helps determine which treatment is most likely to be covered based on the patient's treatment history.
Can They Be Used Together?
Yes. TMS and SPRAVATO are not mutually exclusive. For some patients, a sequential or combined approach produces better outcomes than either treatment alone. Emerging research also supports pairing SPRAVATO with cognitive behavioral therapy to extend and deepen the relief the medication provides.
At Georgia Behavioral Health, treatment planning is individualized. Some patients begin with SPRAVATO for rapid stabilization and transition to TMS for longer-term maintenance. Others use TMS as the primary treatment and add SPRAVATO if additional support is needed.
Which Treatment Is Right for You?
There is no universal answer. The right treatment depends on several factors that can only be assessed through a thorough evaluation.
Factors that may favor TMS:
- Preference for a non-medication approach
- History of sensitivity to pharmacological side effects
- Ability to commit to a daily treatment schedule for six weeks
- Depression that is significant but not acutely urgent
- Prior response to brain stimulation approaches
Factors that may favor SPRAVATO:
- Need for faster symptom relief
- Severe or treatment-resistant depression that has not responded to multiple medication trials
- Active suicidal ideation alongside depression
- Preference for a less frequent treatment schedule after the initial phase
- History of response to ketamine or esketamine
Many patients find that a conversation with a psychiatrist who specializes in treatment-resistant depression is the most important first step. The clinical picture, treatment history, and personal circumstances all shape which path makes the most sense.
You Have More Options Than You Think
One of the most important things to understand about treatment-resistant depression is that the options have expanded significantly in recent years. Failing to respond to antidepressants is not the end of the road. It is a signal that a different mechanism is needed.
Both TMS and SPRAVATO target the neurobiology of depression through pathways that traditional medications do not reach. For many patients, one or both of these treatments provides relief they had stopped believing was possible.
Advanced Depression Treatment in Norcross, GA
At Georgia Behavioral Health, we offer both TMS therapy and SPRAVATO for patients with treatment-resistant depression. Our evaluation process is designed to identify which treatment, or combination of treatments, is most likely to produce lasting results for each individual patient.
If depression has not responded to standard treatment, we encourage you to reach out. A comprehensive evaluation is the first step toward finding a path that works.